First MRNA Flu Vaccine mFlusiva Approved By FDA For Adults Over 50

The U.S. Food and Drug Administration (FDA) has approved mFlusiva, the first messenger RNA (mRNA) influenza vaccine developed by Moderna. The drug is indicated for adults aged 50 and older.

Photo: Pravda.ru by Marina Lebedeva is licensed under Free for commercial use

Pharmaceutical worker checking a glass bottle in production

The regulator applied two different approval pathways: adults aged 50 to 64 received standard approval, while those aged 65 and older were granted accelerated approval. This distinction addresses the need for more effective options for older adults, who often exhibit a diminished immune response to traditional vaccines.

Mechanism and Clinical Data

Unlike conventional vaccines that use inactivated or weakened viruses, mRNA technology delivers genetic instructions to cells. These instructions prompt the body to produce a specific viral protein, which the immune system recognizes as foreign and develops a defense against.

Approval was based on clinical trials confirming the vaccine's safety profile and its ability to trigger a significant immune response. The synthetic nature of mRNA production removes the need for chicken embryos used in traditional manufacturing, which potentially shortens the production cycle and allows for faster adaptation to mutating seasonal strains.

According to physician and evidence-based prevention specialist Anna Kuznetsova, this approach may offer more reliable protection against severe influenza complications for patients over 50 experiencing immune senescence (the natural aging of the immune system).

Impact on Prevention

Older adults frequently experience limited efficacy from traditional flu shots, leading to higher hospitalization rates during epidemics. The shift toward biotechnology may alter prevention strategies for influenza and other respiratory infections. Researchers are currently evaluating mRNA applications for respiratory diseases where standard preventive methods remain insufficient.

Vaccine Characteristics

The mRNA vaccine serves as an alternative to traditional shots with a different method of immune stimulation. Because it contains only the protein code and no live or fragmented virus, it cannot cause the flu. The choice of vaccine depends on a patient's health status and availability, as determined by a healthcare provider.

Important: This article is for general information and does not replace medical advice. Do not start, stop, or change treatment without a qualified clinician.